CA2387844C - Treatment of emphysema using rar selective retinoid antagonists - Google Patents

Treatment of emphysema using rar selective retinoid antagonists Download PDF

Info

Publication number
CA2387844C
CA2387844C CA002387844A CA2387844A CA2387844C CA 2387844 C CA2387844 C CA 2387844C CA 002387844 A CA002387844 A CA 002387844A CA 2387844 A CA2387844 A CA 2387844A CA 2387844 C CA2387844 C CA 2387844C
Authority
CA
Canada
Prior art keywords
alkyl
carbons
rar
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002387844A
Other languages
English (en)
French (fr)
Other versions
CA2387844A1 (en
Inventor
Paula Nanette Belloni
Michael Klaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2387844A1 publication Critical patent/CA2387844A1/en
Application granted granted Critical
Publication of CA2387844C publication Critical patent/CA2387844C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002387844A 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid antagonists Expired - Fee Related CA2387844C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
US60/160,415 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Publications (2)

Publication Number Publication Date
CA2387844A1 CA2387844A1 (en) 2001-05-03
CA2387844C true CA2387844C (en) 2009-04-14

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387844A Expired - Fee Related CA2387844C (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid antagonists

Country Status (33)

Country Link
US (1) US6300350B1 (enExample)
EP (1) EP1225878B1 (enExample)
JP (2) JP4074458B2 (enExample)
KR (1) KR100485581B1 (enExample)
CN (1) CN1201730C (enExample)
AR (1) AR029648A1 (enExample)
AT (1) ATE344661T1 (enExample)
AU (1) AU777325B2 (enExample)
BR (1) BR0015225A (enExample)
CA (1) CA2387844C (enExample)
CY (1) CY1105941T1 (enExample)
CZ (1) CZ20021657A3 (enExample)
DE (1) DE60031790T2 (enExample)
DK (1) DK1225878T3 (enExample)
ES (1) ES2274810T3 (enExample)
HR (1) HRP20020329A2 (enExample)
HU (1) HUP0203295A3 (enExample)
IL (1) IL149151A0 (enExample)
JO (1) JO2178B1 (enExample)
MA (1) MA26835A1 (enExample)
MX (1) MXPA02003843A (enExample)
MY (1) MY129001A (enExample)
NO (1) NO328738B1 (enExample)
NZ (1) NZ518118A (enExample)
PE (1) PE20010678A1 (enExample)
PL (1) PL357499A1 (enExample)
PT (1) PT1225878E (enExample)
RS (1) RS50165B (enExample)
RU (1) RU2257383C2 (enExample)
TR (1) TR200201071T2 (enExample)
TW (1) TWI288639B (enExample)
WO (1) WO2001030326A1 (enExample)
ZA (1) ZA200202576B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
WO2003024921A1 (en) 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
ATE427929T1 (de) 2001-09-18 2009-04-15 Hoffmann La Roche Substituierte harnstoff retinoid agonisten ii
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
ES2481167T3 (es) 2003-08-22 2014-07-29 Dupont Nutrition Biosciences Aps Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
WO2008063842A2 (en) * 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
US9949996B2 (en) 2011-06-24 2018-04-24 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
SI2931713T1 (sl) 2012-12-17 2017-03-31 Parion Sciences, Inc. Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice
US9963439B2 (en) 2013-08-20 2018-05-08 University Of Washington Through Its Center For Commercialization Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase
EP3039126B1 (en) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139216B1 (ko) * 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
ATE256130T1 (de) * 1993-08-19 2003-12-15 Janssen Pharmaceutica Nv Gefässverengende dihydrobenzopyranderivate
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
ATE185799T1 (de) * 1995-02-24 1999-11-15 Hoffmann La Roche Retinoide
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
ATE334673T1 (de) * 1997-11-12 2006-08-15 Hoffmann La Roche Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
WO2000061232A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
MXPA02000828A (es) * 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
TWI288639B (en) 2007-10-21
DE60031790D1 (de) 2006-12-21
NO20021823L (no) 2002-04-18
JP2003512418A (ja) 2003-04-02
EP1225878A1 (en) 2002-07-31
AU777325B2 (en) 2004-10-14
BR0015225A (pt) 2002-07-16
US6300350B1 (en) 2001-10-09
JP2007302689A (ja) 2007-11-22
AR029648A1 (es) 2003-07-10
CN1382042A (zh) 2002-11-27
JO2178B1 (en) 2003-04-23
HUP0203295A3 (en) 2003-04-28
WO2001030326A1 (en) 2001-05-03
YU29002A (sh) 2005-06-10
HRP20020329A2 (en) 2004-04-30
KR100485581B1 (ko) 2005-04-27
CY1105941T1 (el) 2011-04-06
RS50165B (sr) 2009-05-06
DE60031790T2 (de) 2007-09-20
IL149151A0 (en) 2002-11-10
JP4850791B2 (ja) 2012-01-11
TR200201071T2 (tr) 2002-08-21
NZ518118A (en) 2004-02-27
CZ20021657A3 (cs) 2002-10-16
RU2257383C2 (ru) 2005-07-27
ATE344661T1 (de) 2006-11-15
PT1225878E (pt) 2007-01-31
MA26835A1 (fr) 2004-12-20
HK1051002A1 (zh) 2003-07-18
KR20020043640A (ko) 2002-06-10
AU1137401A (en) 2001-05-08
DK1225878T3 (da) 2007-03-05
MXPA02003843A (es) 2002-09-30
CA2387844A1 (en) 2001-05-03
MY129001A (en) 2007-03-30
ZA200202576B (en) 2003-09-23
PE20010678A1 (es) 2001-07-04
PL357499A1 (pl) 2004-07-26
HUP0203295A2 (hu) 2003-01-28
ES2274810T3 (es) 2007-06-01
NO20021823D0 (no) 2002-04-18
NO328738B1 (no) 2010-05-03
CN1201730C (zh) 2005-05-18
JP4074458B2 (ja) 2008-04-09
EP1225878B1 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
JP4850791B2 (ja) Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療
JPH013193A (ja) 細胞、組織修復剤
US6794416B2 (en) Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid
AU735382B2 (en) Use of alpha-rar antagonists for inhibition of mucin secretion
US20020019438A1 (en) Thiophene derivatives
US20240366729A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
EP4346789A1 (en) Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
CA2037088A1 (en) Prostaglandins for inhibiting cartilage damage
US20050209204A1 (en) Treatment of age-related lung abnormalities using estrogen and/or retinoids
MXPA00008580A (en) Use of alpha-rar antagonists for inhibition of mucin secretion
US20120295982A1 (en) Treating human male copd patients with oral bedoradrine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131015